Publication:
Tight control for Crohn-s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Simple item page
dc.contributor.authorPanaccione, Remo
dc.contributor.authorColombel, Jean-Frederic
dc.contributor.authorTravis, Simon P. L.
dc.contributor.authorBossuyt, Peter
dc.contributor.authorBaert, Filip
dc.contributor.authorVanasek, Tomas
dc.contributor.authorDanalioglu, Ahmet
dc.date.accessioned2020-10-22T18:12:39Z
dc.date.available2020-10-22T18:12:39Z
dc.description.abstractObjective To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn-s disease (CD) naive to immunosuppressants and biologics using a UK public payer perspective.
dc.identifier.citationPanaccione R., Colombel J., Travis S. P. L. , Bossuyt P., Baert F., Vanasek T., Danalioglu A., Novacek G., Armuzzi A., Reinisch W., et al., -Tight control for Crohn-s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial-, GUT, cilt.69, ss.658-664, 2020
dc.identifier.doi10.1136/gutjnl-2019-318256
dc.identifier.pubmed31285357
dc.identifier.scopus85068560085
dc.identifier.urihttp://hdl.handle.net/20.500.12645/24070
dc.identifier.urihttps://gut.bmj.com/content/69/4/658.long
dc.identifier.wosWOS:000521111900007
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCrohn-s disease
dc.titleTight control for Crohn-s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
dc.typeArticle
dspace.entity.typePublication
local.avesis.id815d9d46-ed04-4a8a-825c-facf9f610cab
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus
local.publication.isinternational1

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Tight control for Crohn's disease.pdf
Size:
676.74 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Yayınlar - Eserler